Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Behunin

Ophthalmology Ann Arbor, MI Medical Doctor

NPI 1235575242 CMS profile 540811

1000 Wall Street, Ann Arbor, MI 48105

Open in the dashboard

General payments

$1,100

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Behunin of Ann Arbor, MI is reported in the CMS Open Payments database as having received $1,100 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $201 6
2023 General $112 5
2022 General $192 5
2021 General $335 12
2020 General $117 4
2019 General $144 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Behunin
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Nicholas Behunin were reported at $201. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Nicholas Behunin Ophthalmology median Middle half National median
2019 $144 $258 $104–$655 $163
2020 $117 $126 $45–$321 $114
2021 $335 $205 $76–$534 $132
2022 $192 $266 $100–$678 $149
2023 $112 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $201 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $604 16 payments
  2. Allergan Inc. $114 4 payments
  3. Mallinckrodt Hospital Products Inc. $92 4 payments
  4. Sun Pharmaceutical Industries Inc. $66 3 payments
  5. Novartis Pharmaceuticals Corporation $55 3 payments
  6. TissueTech, Inc. $51 3 payments
  7. Bausch & Lomb, a division of Bausch Health US, LLC $39 2 payments
  8. Glaukos Corporation $28 1 payment
  9. Dompe US, Inc. $18 1 payment
  10. Tarsus Pharmaceuticals, Inc. $17 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,100 39 payments
Products named General payments · program years 2019–2025
  1. Clareon Ophthalmology $237 6 payments
  2. AcrySof IQ PanOptix $129 1 payment
  3. Clareon Ophthalmology $110 1 payment
  4. ACTHAR $92 4 payments
  5. ARGOS $87 6 payments
  6. ILUMYA $43 2 payments
  7. DURYSTA $43 2 payments
  8. VYZULTA $39 2 payments
  9. iStent inject Trabecular Micro-Bypass Stent System $28 1 payment
  10. Rocklatan $23 1 payment
  11. Other $206 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,647

Median for Ophthalmology: 891

Drug cost

$52,826

Median for Ophthalmology: $68,233

Branded share of claims

22%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 395 $11,887
Restasis Cyclosporine Brand 15 $10,625
Xiidra Lifitegrast Brand 11 $10,221
Cyclosporine Generic 19 $4,853
Ketorolac Tromethamine Generic 155 $2,920
Latanoprost Generic 266 $2,250
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 139 $1,995
Timolol Maleate Generic 248 $1,639
Ofloxacin Generic 125 $1,590
Valacyclovir Valacyclovir Hcl Brand 38 $1,235

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$367,519

Medicare's payments for the services billed

Medicare patients

964

Average age 76

Services billed

3,660

564 women, 400 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 47%
Diabetes 24%
Chronic kidney disease 22%
Ischemic heart disease 21%
Depression 20%
Osteoporosis 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record